Vitamin C and B3 as new biomaterials to alter intestinal stem cells

Yijun Qi, Jo Lohman, Kaitlin M. Bratlie, Nathan Peroutka-Bigus, Bryan Bellaire, Michael Wannemuehler, Kyoung Jin Yoon, Terrence A. Barrett, Qun Wang

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Vitamin C (ascorbic acid) and vitamin B3 (niacin) have been extensively studied since the 20th century. In the area of stem cell biology, vitamin C has shown its direct impact toward homeostasis and epigenetic changes (D'Aniello et al., Stem Cells International, 2017, 1–16). Vitamin B3 aids in maintaining healthy intestinal homeostasis and reducing gut inflammation by participating in the rapamycin signaling pathway (Kumar et al., The American Journal of Physiology-Gastrointestinal and Liver Physiology, 2013). In this study, vitamin C and vitamin B3 (600 and 1,200 μg/mL) have been explored as potential new biomaterials to study their effects on four types of intestinal stem cells which are isolated from mice bearing different microbiota. We observed that C3H ASF and 129 ASF IL-10 are more sensitive towardB7 600 μg/mL vitamin B3 and 1,200 μg/mL vitamin C. The lowest growth rate and viability for all types of organoids was with 1,200 μg/mL vitamin C. From quantitative polymerase chain reaction analysis (qPCR analysis), MUC2 was upregulated for 129 ASF and C3H Conv when exposed to 600 μg/mL and 1,200 μg/mL vitamin C. It suggests that large amounts of glycoprotein may be produced after adding high concentrations of vitamin C. Since inflammatory bowel disease has low level of MUC2, this finding may be helpful in restoring mucosal health by upregulating the MUC2 gene while altering patient's microbiota (Sibila et al., Annals of the American Thoracic Society, 2016). These results are expected to have a positive translational impact because this bottom-up strategy would be instrumental in developing Vitamin C and B3 based orally available therapeutic strategies and formula for advancing the fields of gastrointestinal regenerative medicine.

Original languageEnglish
Pages (from-to)1886-1897
Number of pages12
JournalJournal of Biomedical Materials Research - Part A
Volume107
Issue number9
DOIs
StatePublished - Sep 2019

Bibliographical note

Funding Information:
Crohn’s & Colitis Foundation of America, Grant/Award Number: 348137; McGee-Wagner Interdisciplinary Research Foundation; National Institutes of Health, Grant/Award Number: 2RO1 DK095662; PhRMA Foundation Research Starter Award, Grant/ Award Number: 348137; VA Merit, Grant/ Award Number: 1I01CX001353

Funding Information:
Dr. Wang is grateful for the support from Crohn's & Colitis Foundation of America (CCFA) Career Award (No. 348137), Pharmaceutical Research and Manufacturers of America Foundation Research Starter Award (No. RSGTMT17), and McGee-Wagner Interdisciplinary Research Foundation. The research was also supported (TAB) by NIH (2RO1 DK095662) and VA Merit (1I01CX001353) grants.

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

Keywords

  • MUC2
  • PIK3CA
  • intestinal stem cells
  • organoids
  • vitamin B
  • vitamin C

ASJC Scopus subject areas

  • Ceramics and Composites
  • Biomaterials
  • Biomedical Engineering
  • Metals and Alloys

Fingerprint

Dive into the research topics of 'Vitamin C and B3 as new biomaterials to alter intestinal stem cells'. Together they form a unique fingerprint.

Cite this